25 XP   0   0   10

Arecor Therapeutics PLC
Buy, Hold or Sell?

Let's analyse Arecor together

PenkeI guess you are interested in Arecor Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arecor Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Arecor Therapeutics PLC

I send you an email if I find something interesting about Arecor Therapeutics PLC.

Quick analysis of Arecor (30 sec.)










What can you expect buying and holding a share of Arecor? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p56.99
Expected worth in 1 year
p42.70
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
p-14.29
Return On Investment
-10.5%

For what price can you sell your share?

Current Price per Share
p136.50
Expected price per share
p125.00 - p150.00
How sure are you?
50%

1. Valuation of Arecor (5 min.)




Live pricePrice per Share (EOD)

p136.50

Intrinsic Value Per Share

p-576.40 - p-367.90

Total Value Per Share

p-519.41 - p-310.90

2. Growth of Arecor (5 min.)




Is Arecor growing?

Current yearPrevious yearGrowGrow %
How rich?$21.8m$23.1m-$1.3m-6.3%

How much money is Arecor making?

Current yearPrevious yearGrowGrow %
Making money-$11.5m-$7.7m-$3.8m-33.4%
Net Profit Margin-385.4%-532.7%--

How much money comes from the company's main activities?

3. Financial Health of Arecor (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Arecor? (5 min.)

Welcome investor! Arecor's management wants to use your money to grow the business. In return you get a share of Arecor.

What can you expect buying and holding a share of Arecor?

First you should know what it really means to hold a share of Arecor. And how you can make/lose money.

Speculation

The Price per Share of Arecor is p136.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arecor.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arecor, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p56.99. Based on the TTM, the Book Value Change Per Share is p-3.57 per quarter. Based on the YOY, the Book Value Change Per Share is p58.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arecor.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.38-0.3%-0.38-0.3%-0.25-0.2%-0.16-0.1%-0.16-0.1%
Usd Book Value Change Per Share-0.040.0%-0.040.0%0.720.5%0.120.1%0.120.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.040.0%-0.040.0%0.720.5%0.120.1%0.120.1%
Usd Price Per Share3.00-3.00-4.70-1.28-1.28-
Price to Earnings Ratio-7.94--7.94--18.67--4.43--4.43-
Price-to-Total Gains Ratio-67.19--67.19-6.48--30.36--30.36-
Price to Book Ratio4.21-4.21-6.21-1.74-1.74-
Price-to-Total Gains Ratio-67.19--67.19-6.48--30.36--30.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.7050215
Number of shares586
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.12
Usd Total Gains Per Share-0.040.12
Gains per Quarter (586 shares)-26.1569.53
Gains per Year (586 shares)-104.58278.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-105-1150278268
20-209-2200556546
30-314-3250834824
40-418-430011121102
50-523-535013911380
60-628-640016691658
70-732-745019471936
80-837-850022252214
90-941-955025032492
100-1046-1060027812770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.06.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.03.00.050.0%3.03.00.050.0%3.03.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.06.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.03.00.050.0%3.03.00.050.0%3.03.00.050.0%

Fundamentals of Arecor

About Arecor Therapeutics PLC

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products. In addition, the company is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-11 00:59:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Arecor Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Arecor earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • A Net Profit Margin of -385.4% means that -3.85 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arecor Therapeutics PLC:

  • The MRQ is -385.4%. The company is making a huge loss. -2
  • The TTM is -385.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-385.4%TTM-385.4%0.0%
TTM-385.4%YOY-532.7%+147.4%
TTM-385.4%5Y-267.4%-117.9%
5Y-267.4%10Y-267.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-385.4%-207.2%-178.2%
TTM-385.4%-216.8%-168.6%
YOY-532.7%-282.3%-250.4%
5Y-267.4%-436.8%+169.4%
10Y-267.4%-597.3%+329.9%
1.1.2. Return on Assets

Shows how efficient Arecor is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • -42.5% Return on Assets means that Arecor generated -0.43 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arecor Therapeutics PLC:

  • The MRQ is -42.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-42.5%TTM-42.5%0.0%
TTM-42.5%YOY-29.5%-13.1%
TTM-42.5%5Y-47.7%+5.1%
5Y-47.7%10Y-47.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42.5%-13.3%-29.2%
TTM-42.5%-12.8%-29.7%
YOY-29.5%-11.6%-17.9%
5Y-47.7%-13.8%-33.9%
10Y-47.7%-15.6%-32.1%
1.1.3. Return on Equity

Shows how efficient Arecor is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • -53.1% Return on Equity means Arecor generated -0.53 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arecor Therapeutics PLC:

  • The MRQ is -53.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -53.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-53.1%TTM-53.1%0.0%
TTM-53.1%YOY-33.3%-19.8%
TTM-53.1%5Y-111.1%+58.1%
5Y-111.1%10Y-111.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-53.1%-16.9%-36.2%
TTM-53.1%-16.1%-37.0%
YOY-33.3%-14.9%-18.4%
5Y-111.1%-19.3%-91.8%
10Y-111.1%-20.1%-91.0%

1.2. Operating Efficiency of Arecor Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Arecor is operating .

  • Measures how much profit Arecor makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • An Operating Margin of -442.4% means the company generated -4.42  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arecor Therapeutics PLC:

  • The MRQ is -442.4%. The company is operating very inefficient. -2
  • The TTM is -442.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-442.4%TTM-442.4%0.0%
TTM-442.4%YOY-516.1%+73.8%
TTM-442.4%5Y-297.8%-144.6%
5Y-297.8%10Y-297.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-442.4%-298.0%-144.4%
TTM-442.4%-238.5%-203.9%
YOY-516.1%-288.4%-227.7%
5Y-297.8%-486.2%+188.4%
10Y-297.8%-628.4%+330.6%
1.2.2. Operating Ratio

Measures how efficient Arecor is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.42 means that the operating costs are 5.42 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Arecor Therapeutics PLC:

  • The MRQ is 5.424. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.424. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.424TTM5.4240.000
TTM5.424YOY6.161-0.738
TTM5.4245Y3.980+1.444
5Y3.98010Y3.9800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4243.235+2.189
TTM5.4243.310+2.114
YOY6.1613.838+2.323
5Y3.9805.679-1.699
10Y3.9807.823-3.843

1.3. Liquidity of Arecor Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Arecor is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.69 means the company has 4.69 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Arecor Therapeutics PLC:

  • The MRQ is 4.688. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.688. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.688TTM4.6880.000
TTM4.688YOY9.049-4.361
TTM4.6885Y4.432+0.256
5Y4.43210Y4.4320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6883.863+0.825
TTM4.6884.169+0.519
YOY9.0495.337+3.712
5Y4.4326.122-1.690
10Y4.4326.434-2.002
1.3.2. Quick Ratio

Measures if Arecor is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • A Quick Ratio of 6.53 means the company can pay off 6.53 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arecor Therapeutics PLC:

  • The MRQ is 6.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.529TTM6.5290.000
TTM6.529YOY8.772-2.244
TTM6.5295Y4.660+1.869
5Y4.66010Y4.6600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5293.504+3.025
TTM6.5293.991+2.538
YOY8.7725.371+3.401
5Y4.6606.088-1.428
10Y4.6606.395-1.735

1.4. Solvency of Arecor Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Arecor assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arecor to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Arecor assets are financed with 19.8% credit (debt) and the remaining percentage (100% - 19.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arecor Therapeutics PLC:

  • The MRQ is 0.198. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.198. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.198TTM0.1980.000
TTM0.198YOY0.113+0.085
TTM0.1985Y0.379-0.181
5Y0.37910Y0.3790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1980.339-0.141
TTM0.1980.337-0.139
YOY0.1130.271-0.158
5Y0.3790.368+0.011
10Y0.3790.388-0.009
1.4.2. Debt to Equity Ratio

Measures if Arecor is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arecor to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.7% means that company has 0.25 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arecor Therapeutics PLC:

  • The MRQ is 0.247. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.247. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.247TTM0.2470.000
TTM0.247YOY0.128+0.119
TTM0.2475Y1.214-0.968
5Y1.21410Y1.2140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2470.392-0.145
TTM0.2470.403-0.156
YOY0.1280.335-0.207
5Y1.2140.427+0.787
10Y1.2140.461+0.753

2. Market Valuation of Arecor Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Arecor generates.

  • Above 15 is considered overpriced but always compare Arecor to the Biotechnology industry mean.
  • A PE ratio of -7.94 means the investor is paying -7.94 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arecor Therapeutics PLC:

  • The EOD is -4.515. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.938. Based on the earnings, the company is expensive. -2
  • The TTM is -7.938. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.515MRQ-7.938+3.423
MRQ-7.938TTM-7.9380.000
TTM-7.938YOY-18.667+10.729
TTM-7.9385Y-4.434-3.504
5Y-4.43410Y-4.4340.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.515-2.300-2.215
MRQ-7.938-2.656-5.282
TTM-7.938-2.718-5.220
YOY-18.667-4.145-14.522
5Y-4.434-6.258+1.824
10Y-4.434-6.315+1.881
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arecor Therapeutics PLC:

  • The EOD is -3.758. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.607. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.607. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.758MRQ-6.607+2.849
MRQ-6.607TTM-6.6070.000
TTM-6.607YOY-20.866+14.258
TTM-6.6075Y-4.579-2.028
5Y-4.57910Y-4.5790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.758-2.974-0.784
MRQ-6.607-3.306-3.301
TTM-6.607-3.508-3.099
YOY-20.866-5.613-15.253
5Y-4.579-8.378+3.799
10Y-4.579-8.873+4.294
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Arecor is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.21 means the investor is paying 4.21 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Arecor Therapeutics PLC:

  • The EOD is 2.395. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.211. Based on the equity, the company is fair priced.
  • The TTM is 4.211. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.395MRQ4.211-1.816
MRQ4.211TTM4.2110.000
TTM4.211YOY6.208-1.997
TTM4.2115Y1.737+2.475
5Y1.73710Y1.7370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3951.914+0.481
MRQ4.2112.116+2.095
TTM4.2112.097+2.114
YOY6.2082.881+3.327
5Y1.7373.550-1.813
10Y1.7373.936-2.199
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Arecor Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.572-3.5720%58.038-106%9.499-138%9.499-138%
Book Value Per Share--56.99256.9920%60.564-6%24.451+133%24.451+133%
Current Ratio--4.6884.6880%9.049-48%4.432+6%4.432+6%
Debt To Asset Ratio--0.1980.1980%0.113+75%0.379-48%0.379-48%
Debt To Equity Ratio--0.2470.2470%0.128+93%1.214-80%1.214-80%
Dividend Per Share----0%-0%-0%-0%
Eps---30.235-30.2350%-20.142-33%-13.020-57%-13.020-57%
Free Cash Flow Per Share---36.324-36.3240%-18.020-50%-12.041-67%-12.041-67%
Free Cash Flow To Equity Per Share---19.476-19.4760%50.322-139%6.062-421%6.062-421%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---367.895--------
Intrinsic Value_10Y_min---576.404--------
Intrinsic Value_1Y_max---17.432--------
Intrinsic Value_1Y_min---29.968--------
Intrinsic Value_3Y_max---67.188--------
Intrinsic Value_3Y_min---114.646--------
Intrinsic Value_5Y_max---134.799--------
Intrinsic Value_5Y_min---225.640--------
Market Cap4180585500.000-76%7350480000.0007350480000.0000%11515752000.000-36%3144372000.000+134%3144372000.000+134%
Net Profit Margin---3.854-3.8540%-5.327+38%-2.674-31%-2.674-31%
Operating Margin---4.424-4.4240%-5.161+17%-2.978-33%-2.978-33%
Operating Ratio--5.4245.4240%6.161-12%3.980+36%3.980+36%
Pb Ratio2.395-76%4.2114.2110%6.208-32%1.737+142%1.737+142%
Pe Ratio-4.515+43%-7.938-7.9380%-18.667+135%-4.434-44%-4.434-44%
Price Per Share136.500-76%240.000240.0000%376.000-36%102.667+134%102.667+134%
Price To Free Cash Flow Ratio-3.758+43%-6.607-6.6070%-20.866+216%-4.579-31%-4.579-31%
Price To Total Gains Ratio-38.214+43%-67.189-67.1890%6.479-1137%-30.355-55%-30.355-55%
Quick Ratio--6.5296.5290%8.772-26%4.660+40%4.660+40%
Return On Assets---0.425-0.4250%-0.295-31%-0.477+12%-0.477+12%
Return On Equity---0.531-0.5310%-0.333-37%-1.111+109%-1.111+109%
Total Gains Per Share---3.572-3.5720%58.038-106%9.499-138%9.499-138%
Usd Book Value--21803040.50021803040.5000%23169555.900-6%9354151.616+133%9354151.616+133%
Usd Book Value Change Per Share---0.045-0.0450%0.725-106%0.119-138%0.119-138%
Usd Book Value Per Share--0.7120.7120%0.757-6%0.305+133%0.305+133%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.378-0.3780%-0.252-33%-0.163-57%-0.163-57%
Usd Free Cash Flow---13896237.500-13896237.5000%-6893782.900-50%-4606566.716-67%-4606566.716-67%
Usd Free Cash Flow Per Share---0.454-0.4540%-0.225-50%-0.150-67%-0.150-67%
Usd Free Cash Flow To Equity Per Share---0.243-0.2430%0.629-139%0.076-421%0.076-421%
Usd Market Cap52219693.481-76%91814845.68091814845.6800%143843258.232-36%39276350.652+134%39276350.652+134%
Usd Price Per Share1.705-76%2.9982.9980%4.697-36%1.282+134%1.282+134%
Usd Profit---11566666.000-11566666.0000%-7705697.900-33%-4980880.141-57%-4980880.141-57%
Usd Revenue--3001587.3003001587.3000%1446457.800+108%1925133.738+56%1925133.738+56%
Usd Total Gains Per Share---0.045-0.0450%0.725-106%0.119-138%0.119-138%
 EOD+3 -5MRQTTM+0 -0YOY+6 -275Y+15 -1810Y+15 -18

3.2. Fundamental Score

Let's check the fundamental score of Arecor Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.515
Price to Book Ratio (EOD)Between0-12.395
Net Profit Margin (MRQ)Greater than0-3.854
Operating Margin (MRQ)Greater than0-4.424
Quick Ratio (MRQ)Greater than16.529
Current Ratio (MRQ)Greater than14.688
Debt to Asset Ratio (MRQ)Less than10.198
Debt to Equity Ratio (MRQ)Less than10.247
Return on Equity (MRQ)Greater than0.15-0.531
Return on Assets (MRQ)Greater than0.05-0.425
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Arecor Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.051
Ma 20Greater thanMa 50136.875
Ma 50Greater thanMa 100139.960
Ma 100Greater thanMa 200156.900
OpenGreater thanClose136.500
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-05-312019-12-312020-12-312021-12-312022-12-31
Other Current Liabilities  44,57222,59367,1658,70575,87051,530127,400-148,000-20,600
Total Other Income Expense Net -1,5401,174-366-8,065-8,431-88,369-96,800105,6008,800



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in GBP. All numbers in thousands.

Summary
Total Assets21,765
Total Liabilities4,310
Total Stockholder Equity17,455
 As reported
Total Liabilities 4,310
Total Stockholder Equity+ 17,455
Total Assets = 21,765

Assets

Total Assets21,765
Total Current Assets17,477
Long-term Assets4,288
Total Current Assets
Cash And Cash Equivalents 4,765
Short-term Investments 8,041
Net Receivables 3,492
Inventory 1,131
Other Current Assets 48
Total Current Assets  (as reported)17,477
Total Current Assets  (calculated)17,477
+/-0
Long-term Assets
Property Plant Equipment 838
Goodwill 1,484
Intangible Assets 1,918
Other Assets 48
Long-term Assets  (as reported)4,288
Long-term Assets  (calculated)4,288
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,728
Long-term Liabilities582
Total Stockholder Equity17,455
Total Current Liabilities
Short-term Debt 202
Accounts payable 3,526
Other Current Liabilities -206
Total Current Liabilities  (as reported)3,728
Total Current Liabilities  (calculated)3,522
+/- 206
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt86
Other Liabilities 496
Long-term Liabilities  (as reported)582
Long-term Liabilities  (calculated)582
+/-0
Total Stockholder Equity
Common Stock306
Retained Earnings -26,181
Accumulated Other Comprehensive Income 12,340
Other Stockholders Equity 30,990
Total Stockholder Equity (as reported)17,455
Total Stockholder Equity (calculated)17,455
+/-0
Other
Capital Stock306
Cash and Short Term Investments 12,806
Common Stock Shares Outstanding 28,936
Current Deferred Revenue206
Liabilities and Stockholders Equity 21,765
Net Debt -4,477
Net Invested Capital 17,455
Net Tangible Assets 14,053
Net Working Capital 13,749
Property Plant and Equipment Gross 2,198
Short Long Term Debt Total 288



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312019-05-312018-05-312017-05-31
> Total Assets 
2,564
2,067
5,451
4,306
4,284
20,921
21,765
21,76520,9214,2844,3065,4512,0672,564
   > Total Current Assets 
1,896
1,520
4,998
3,916
3,822
20,515
17,477
17,47720,5153,8223,9164,9981,5201,896
       Cash And Cash Equivalents 
1,028
705
3,447
3,074
2,898
18,316
4,765
4,76518,3162,8983,0743,4477051,028
       Short-term Investments 
0
0
0
0
0
0
8,041
8,041000000
       Net Receivables 
690
759
1,495
811
860
1,571
3,492
3,4921,5718608111,495759690
       Inventory 
0
11
0
0
0
0
1,131
1,1310000110
   > Long-term Assets 
668
546
452
342
462
406
4,288
4,288406462342452546668
       Property Plant Equipment 
552
439
353
295
375
328
838
838328375295353439552
       Goodwill 
0
0
0
0
0
0
1,484
1,484000000
       Intangible Assets 
68
60
51
47
38
30
1,918
1,918303847516068
       Long-term Assets Other 
48
48
48
-342
48
-358
-4,240
-4,240-35848-342484848
> Total Liabilities 
1,232
1,396
1,235
1,037
3,510
2,372
4,310
4,3102,3723,5101,0371,2351,3961,232
   > Total Current Liabilities 
959
823
1,107
1,037
1,408
2,267
3,728
3,7282,2671,4081,0371,107823959
       Short-term Debt 
303
87
93
0
105
126
202
20212610509387303
       Accounts payable 
101
165
568
366
464
518
3,526
3,526518464366568165101
       Other Current Liabilities 
556
571
446
672
759
1,274
-206
-2061,274759672446571556
   > Long-term Liabilities 
274
573
128
0
2,102
105
582
5821052,1020128573274
       Other Liabilities 
0
0
0
0
212
0
496
49602120000
> Total Stockholder Equity
1,332
670
4,216
-9,113
774
18,549
17,455
17,45518,549774-9,1134,2166701,332
   Common Stock
16
16
26
27
27
278
306
3062782727261616
   Retained Earnings -26,181-17,051-11,892-9,140-7,862-5,427-4,308
   Accumulated Other Comprehensive Income 
0
0
0
0
1,045
11,974
12,340
12,34011,9741,0450000
   Capital Surplus 
5,623
5,823
0
11,594
11,594
0
0
0011,59411,59405,8235,623
   Treasury Stock0000000



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue2,403
Cost of Revenue-0
Gross Profit2,4032,403
 
Operating Income (+$)
Gross Profit2,403
Operating Expense-13,033
Operating Income-10,630-10,630
 
Operating Expense (+$)
Research Development8,613
Selling General Administrative5,552
Selling And Marketing Expenses0
Operating Expense13,03314,165
 
Net Interest Income (+$)
Interest Income109
Interest Expense-26
Other Finance Cost-0
Net Interest Income83
 
Pretax Income (+$)
Operating Income-10,630
Net Interest Income83
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,542-10,718
EBIT - interestExpense = -10,656
-10,542
-9,234
Interest Expense26
Earnings Before Interest and Taxes (EBIT)-10,630-10,516
Earnings Before Interest and Taxes (EBITDA)-10,175
 
After tax Income (+$)
Income Before Tax-10,542
Tax Provision--1,282
Net Income From Continuing Ops-9,260-9,260
Net Income-9,260
Net Income Applicable To Common Shares-9,260
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses13,033
Total Other Income/Expenses Net88-83
 

Technical Analysis of Arecor
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arecor. The general trend of Arecor is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arecor's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arecor Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 150.00 < 150.00 < 150.00.

The bearish price targets are: 125.00 > 125.00.

Tweet this
Arecor Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arecor Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arecor Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arecor Therapeutics PLC. The current macd is -2.303046.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arecor price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Arecor. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Arecor price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Arecor Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartArecor Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arecor Therapeutics PLC. The current adx is 16.09.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arecor shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Arecor Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arecor Therapeutics PLC. The current sar is 138.00.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arecor Therapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arecor Therapeutics PLC. The current rsi is 48.05. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Arecor Therapeutics PLC Daily Relative Strength Index (RSI) ChartArecor Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arecor Therapeutics PLC. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arecor price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Arecor Therapeutics PLC Daily Stochastic Oscillator ChartArecor Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arecor Therapeutics PLC. The current cci is -6.94133107.

Arecor Therapeutics PLC Daily Commodity Channel Index (CCI) ChartArecor Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arecor Therapeutics PLC. The current cmo is 6.98756677.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arecor Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartArecor Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arecor Therapeutics PLC. The current willr is -34.28571429.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arecor is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arecor Therapeutics PLC Daily Williams %R ChartArecor Therapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arecor Therapeutics PLC.

Arecor Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arecor Therapeutics PLC. The current atr is 5.0775371.

Arecor Therapeutics PLC Daily Average True Range (ATR) ChartArecor Therapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arecor Therapeutics PLC. The current obv is -446,590.

Arecor Therapeutics PLC Daily On-Balance Volume (OBV) ChartArecor Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arecor Therapeutics PLC. The current mfi is 13.34.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Arecor Therapeutics PLC Daily Money Flow Index (MFI) ChartArecor Therapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arecor Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Arecor Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arecor Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.051
Ma 20Greater thanMa 50136.875
Ma 50Greater thanMa 100139.960
Ma 100Greater thanMa 200156.900
OpenGreater thanClose136.500
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Arecor with someone you think should read this too:
  • Are you bullish or bearish on Arecor? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arecor? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arecor Therapeutics PLC

I send you an email if I find something interesting about Arecor Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Arecor Therapeutics PLC.

Receive notifications about Arecor Therapeutics PLC in your mailbox!